Viral enanthema in oral mucosa: A possible diagnostic challenge in the COVID‐19 pandemic

Abstract

Dear Editor, Caused by SARS-CoV-2, the coronavirus disease 2019 (COVID-19) is a potentially deadly coronavirus-associated acute respiratory illness whose most common symptoms are cough, fever, fatigue, sputum production, and shortness of breath (Guan et al., 2020). Although only 0.2% of the 1,099 patients evaluated by Guan et al. (2020) developed cutaneous lesions, recent articles have reported relevant eruptive skin rash (i.e., exanthema) sometimes involving mucous membrane (i.e., enanthema) in COVID-19 patients (Chaux-Bodard, Deneuve, & Desoutter, 2020; Galván Casas et al., 2020; Martín Carreras-Presas, Amaro Sánchez, López -Sánchez, Jané -Salas, & Somacarrera Pérez, 2020; Recalcati, 2020; Suchonwanit, Leerunyakul, & Kositkuljorn, 2020). Recalcati (2020), for example, reported that 20.4% of 88 COVID-19 patients presented cutaneous manifestations such as erythematous rash, generalized urticaria, and vesicles. They suggested that the skin lesions were similar to ones found in common viral diseases but emphasized that additional studies are necessary to confirm its association with COVID-19. Other authors, after reviewing 18 articles reporting cutaneous lesions in COVID-19 patients, suggested that the possible cutaneous manifestations of the virus may be classified into two groups—viral exanthema and vasculopathy-related skin manifestation—but highlighted the possibility of secondary cutaneous reactions to treatment as well (Suchonwanit et al., 2020). In a dermatological case collection survey of COVID-19 patients, Galván Casas et al. (2020) classified the cutaneous manifestations in five clinical patterns: maculopapular eruptions, urticarial lesions, pseudo-chilblains, other vesicular eruptions, and livedo or necrosis. The authors also reported that some patients presented other manifestations such as enanthema. In an atlas published as supplementary material, the authors presented the case of a patient with maculopapular eruption in the oral mucosa (i.e., enanthema) localized in the palate, palatal gingiva, lower buccal gingiva, and lower lip mucosa. Oral manifestations of earlier coronavirus-related diseases such as Middle East respiratory syndrome (MERS) are ill-defined (Scully & Samaranayake, 2016). Concerning COVID-19, to the best of our knowledge, only two reports specifically address oral enanthema. First, Martín Carreras-Presas et al. (2020) described oral lesions in one confirmed and two suspected patients; the confirmed patient presented blisters in the internal lip mucosa, desquamative gingivitis, and widespread skin rash, while the other two cases presented painful palatal ulcers similar to herpetic lesions. Second, Chaux-Bodard et al. (2020) reported an oral lesion as a possible inaugural symptom of COVID-19 in a patient exhibiting painful inflammation of the tongue papillae on Day 1, which evolved into an erythematous macule and subsequently into an asymptomatic ulcer. An erythematous skin lesion developed on Day 3, and the positive diagnostic test was performed on Day 8. In this context, when health professionals, especially dentists, are faced with enanthema in oral mucosa as a possible diagnostic challenge in the COVID-19 pandemic, it is important to review some of the main viral diseases associated with oral enanthema, as illustrated in Table 1 (Castro & Ramos-e-Silva, 2020; Drago et al., 2017; Santosh & Muddana, 2020; Scully & Samaranayake, 2016). Such action is especially relevant in tropical countries such as Brazil, where other viral diseases are in endemic transmission. Viral disease Herpes zoster infection (i.e., shingles): Unilateral painful vesicular lesions in areas supplied by the trigeminal nerve This study was financed in part by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior—Brazil (CAPES)—Finance Code 001. The authors are also grateful to the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) (437861/2018-0) and the Fundação de Amparo à Pesquisa do Estado de Minas Gerais (FAPEMIG). BAR has a CAPES fellowship. MCRH is a research fellow of FAPEMIG (CDS-PPM-00653-16). None to declare. Breno Amaral Rocha: Conceptualization; Writing-original draft. Giovanna Ribeiro Souto: Conceptualization; Writing-original draft. SORAYA M C GROSSMANN: Conceptualization; Writing-original draft. Maria Cássia Ferreira Aguiar: Conceptualization; Writing-original draft. Bruno Augusto Benevenuto Benevenuto de Andrade: Conceptualization; Writing-original draft. Mário Romañach: Conceptualization; Writing-original draft. Martinho Campolina Rebello Horta: Conceptualization; Writing-original draft.

Topics & Concepts